Royalty Pharma (RPRX) Capital Expenditures Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Capital Expenditures Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -40.95% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -32.58% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 60.74% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 29.63% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.08% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.74% |
| Mar 31, 2026 | -9.07% |
| Dec 31, 2025 | 43.13% |
| Sep 30, 2025 | -9.93% |
| Jun 30, 2025 | -81.47% |
| Mar 31, 2025 | 131.68% |
| Dec 31, 2024 | 42.45% |
| Sep 30, 2024 | -3.66% |
| Jun 30, 2024 | 59.17% |
| Mar 31, 2024 | -44.48% |
| Dec 31, 2023 | 7.57% |
| Sep 30, 2023 | -17.47% |
| Jun 30, 2023 | -49.71% |
| Mar 31, 2023 | 82.32% |
| Dec 31, 2022 | -18.76% |
| Sep 30, 2022 | 286.57% |